Primary aim: -To assess the effect of metformin use on the treatment of minimal hepatic encephalopathy in patients with liver cirrhosis. Secondary aim: -To evaluate if metformin is a safety drug in patients showing liver cirrhosis.
In this study, 30 patients will be included divided in two arms. Investigators and patients will not know the treatment used (double blind). Arm 1: Metformin 1000mg twice a day (2000 mg/day), during 12 weeks. Arm 2: Placebo 1000mg twice a day (2000mg/day), during 12 weeks. At the end of the study, patients will be followed-up 8 weeks more to control the appearance of adverse effects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
30
Fundación Pública Andaluza para la Gestión de la investigación en salud de Sevilla (FISEVI)
Seville, Spain
RECRUITINGNumber of patients with Minimal hepatic encephalopathy
Measurement of the results of critical flicker frequency after 12 weeks of metformin treatment
Time frame: 12 weeks
Number of patients with Minimal hepatic encephalopathy
Measurement of the results of PHES after 12 weeks of metformin treatment
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.